View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 9, 2022

Iterative Scopes and Pfizer enter AI-driven agreement to support IBD trials

Under the agreement, Iterative Scopes will gain access to an IBD clinical trial database of Pfizer.

Iterative Scopes and Pfizer have signed an artificial intelligence-driven data sharing agreement to advance clinical trials for inflammatory bowel disease (IBD).

The agreement is aimed at expediting the development of potential new therapies to treat patients with IBD globally.

Under the deal, Iterative Scopes will gain access to an IBD clinical trial database of Pfizer, which will aid the former in improving its disease severity scoring algorithms.

Disease severity scoring systems, such as the Mayo Endoscopic Score (MES), are presently utilised for meeting inclusion criteria in IBD clinical trials, as well as to assess primary and secondary endpoints. 

Such metrics are subjective and based on the experience and intuition of the physician.

Furthermore, they pose subject recruitment and workflow challenges. 

These challenges can be resolved by combining computational algorithms of Iterative Scopes with existing colonoscopy imagery to decide on eligibility for the trials. 

The computational software automates colonoscopy video interpretation, aiding the trial investigators to attain standardised MES scores for individual patients.

Iterative Scopes Engineering senior vice-president Jean-Pierre Schott said: “We are excited to harness machine learning and computer vision to ultimately aid physicians and help them improve clinical outcomes for IBD patients earlier and with greater success. 

“This agreement will leverage certain Pfizer patient research, along with the Iterative Scopes technological advancements to assess colon health faster and with greater granularity, and possibly improve the quality of life for thousands of patients.”

In December last year, Iterative and its investors raised $150m in a Series B funding round.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy